Browsing: survival

In an interim analysis of the phase III ELEVATE trial reported in The New England Journal of Medicine, Yue et al found that patients with completely resected ALK-positive non–small cell lung cancer (NSCLC) who received adjuvant ensartinib experienced significantly longer disease-free survival than those receiving placebo. The investigators conducted the study to determine whether the…

Low brain metabolism as measured from 18F-FDG PET/CT is associated with higher mortality in patients with advanced non–small cell lung cancer (NSCLC), according to new research published in the July issue of The Journal of Nuclear Medicine. Incorporating brain 18F-FDG uptake alongside clinical, tumor, and biological data improved prediction of overall survival, providing physicians with…